The Safety Features Oversight Group (comprising IMVO, HPRA, PSI, Department of Health, HSE and Private Hospitals Association) continues to oversee progress with FMD implementation in Ireland. Because of the unique circumstances in which we find ourselves this year and the need to ensure that the medicines supply chain can cope with whatever challenges the Covid-19 situation and Brexit may bring over the next 2-3 months, the Group has decided that FMD will remain in a use and learn phase into 2021. In the meantime, the advice is as follows:
The Safety Features Oversight Group will closely monitor the situation over the coming weeks and new dates for ending the use and learn period will be notified in due course.